Zobrazeno 1 - 10
of 49
pro vyhledávání: ''
Autor:
Jean El Cheikh, Iman Abou Dalle, Jeries Kort, Farouk Al Chami, Maya Charafeddine, Haidar El Darsa, Rola El Sayed, Ali Ibrahim, Ali Bazarbachi
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:711-719
Background Intensified immunochemotherapy with rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP) improves outcomes in younger adults with diffuse large B-cell lymphomas (DLBCL) compared with R-CHOP. Due to vinde
Autor:
Rasmus T. Hoeg, Matthew E. Tenold, Rajeev Krishnan, Mehrdad Abedi, Brian A. Jonas, Aaron S. Rosenberg, Joseph Tuscano, Benjamin N Moskoff
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e611-e618
Background FLAG ± Ida (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin), is a salvage chemotherapy regimen for relapsed or refractory (R/R) acute myeloid leukemia (AML), with complete remission (CR) rates historically
Autor:
Jörn C. Albring, Christoph Schliemann, Matthias Stelljes, Christoph Groth, Patrick Stelmach, Christian Reicherts, Wolfgang E. Berdel, Georg Lenz, Klaus Wethmar, Jan-Henrik Mikesch, Daniela V. Wenge
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:e724-e733
Background Blinatumomab and inotuzumab ozogamicin are now widely used to treat relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). Patients and Methods We have reported the clinical course of 34 adult patients with r/r B-ALL recei
Autor:
R J Ma, Jianmin Guo, Zhongwen Liu, Xiangli Chen, L Jiang, Jie Shi, X L Yuan, Jing Yang, Zunmin Zhu, Yin Zhang, Xiaojian Zhu, Yuzhu Zang, Pingchong Lei, Shiwei Yang, Lin Zhang
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:e382-e391
Introduction The purpose of this study was to explore the outcomes of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) plus idarubicin (IDA) as a frontline treatment in adult patients with acute promyelocytic leukemia (APL). Patients and Met
Autor:
Yu Yagi, Eriko Nakashima, Motohiko Ikeda, Yoshimichi Tachikawa, Eriko Fujioka, Takamitsu Matsushima, Hayato Utsunomiya, Youko Suehiro, Tatsuro Goto, Akiko Takamatsu, Hiroshi Takatsuki, Hirofumi Ohno, Taisuke Narazaki, Hiroki Muta, Makoto Oyama, Akie Hirata, Mariko Tsuda, Mitsuo Kozuru, Yuji Yufu, Ilseung Choi, Naokuni Uike, Emi Tanaka, Shojiro Haji, Kaname Miyashita, Junichi Kiyasu, Yasuhiro Tsukamoto, Yasuhiro Nakashima
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:e445-e453
Background We retrospectively analyzed patients with untreated aggressive adult T-cell leukemia/lymphoma who received the modified EPOCH (mEPOCH) regimen. Patients and Methods Patients received up to 6 mEPOCH cycles. Etoposide (50 mg/m2/day), doxorub
Autor:
Noridza Rivera, Caroline Rivera, Idalia Liboy, Wandaly I. Pardo, Fernando Cabanillas, Pedro Gil Solivan, Mirelis Acosta
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:776-783
Purpose To evaluate the impact of lenalidomide in patients with aggressive lymphoma who experienced less than complete response (CR) or as maintenance therapy after CR after gemcitabine, rituximab, and oxaliplatin salvage chemotherapy (GROC-Rev regim
Autor:
Mark Kriegsmann, Patrick Wuchter, Katharina Kriegsmann, Mathias Witzens-Harig, Eike C. Buss, Martin Cremer, Manfred Hensel, Gerlinde Egerer, Julia S. Klee, Anthony D. Ho
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e581-e587
Malignant lymphoma is still the leading cause of death among AIDS-related diseases.We performed a retrospective analysis of 50 HIV-positive lymphoma patients. The median interval between HIV and malignant lymphoma diagnosis was 4 years. Eight patient
Autor:
Rohtesh S. Mehta, Elisabet E. Manasanch, Lei Feng, Chutima Kunacheewa, Sairah Ahmed, Donna M. Weber, Robert Z. Orlowski, Krina K. Patel, Samer Tabchi, Rajit Nair, Sheeba K. Thomas, Behrang Amini, Hans C. Lee, M.H. Qazilbash, Raymond Alexanian, Qaiser Bashir
Publikováno v:
Clin Lymphoma Myeloma Leuk
Background Multiple myeloma (MM) usually follows a clinical course leading to refractoriness and limited treatment options in advanced stages, which might need bridge therapies to either autologous stem cell transplantation or novel therapies. We rep
Autor:
Ernesto Ayala, Adharsh Ravindran, Lubomir Sokol, Pedro Horna, Sarah Mushtaq, Bhagirathbhai Dholaria, Mohamed A. Kharfan-Dabaja, Celeste M. Bello, Julio C. Chavez, Abu-Sayeef Mirza, Ambuj Kumar, Mohammad Hussaini
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e513-e520
Background Primary effusion lymphoma (PEL) is a rare type of non-Hodgkin lymphoma. The limited disease-free survival after chemotherapy has resulted in a poor prognosis. The outcomes data for high-dose therapy followed by autologous hematopoietic cel
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e205-e212
Background Patients who achieve complete remission (CR) with incomplete blood count recovery (CRi) in acute myeloid leukemia (AML) have inferior overall survival and lower progression-free survival. The aim of this study was to define whether blood c